Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Product

Ezetimibe

Aliases
Ezetimibe 10mg, Ezetimibe 10 mg, MK-0653, Placebo for Ezetimibe (4 other aliases)
Name
Zetia
INN Name
Ezetimibe
FDA Approved
Yes

32 clinical trials

6 organizations

13 indications

3 documents

Indication
Hypercholesterolemia
Indication
Atherosclerotic Cardiovascular Disease
Indication
Dyslipidemia
Indication
Hyperlipidemia
Indication
lipid metabolism disorder
Indication
Homozygous Familial Hypercholesterolemia
Indication
Type 2 Diabetes
Indication
Low-Density-Lipoprotein-Type [LDL] Hyperlipoproteinemia
Indication
Metabolic Syndrome
Indication
Type 1 Diabetes
Indication
Inflammation
Indication
Atherosclerosis
Indication
Familial Hypercholesterolemia
Clinical trial
A Phase 2 ,Multicentre, Randomised, Double Blind Double Simulation, Placebo and Positive Controlled Study to Evaluate the Efficacy and Safety of HSK31679 in Patients With Hypercholesterolemia With Non-alcoholic Fatty Liver Disease
Status: Completed, Estimated PCD: 2024-02-20
Clinical trial
A Double-blind, Randomized, Placebo- and Active-Comparator Controlled Study to Evaluate the Efficacy of Inclisiran as Monotherapy in Patients With Primary Hypercholesterolemia Not Receiving Lipid-Lowering Therapy (VictORION-Mono)
Status: Recruiting, Estimated PCD: 2024-06-21
Clinical trial
In Silico Non Interventional Secondary Use of Data Study Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Patients With Established Cardiovascular Disease
Status: Completed, Estimated PCD: 2023-12-15
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Study Followed by an Open Label Treatment Period to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia
Status: Completed, Estimated PCD: 2021-01-14
Clinical trial
A Placebo-Controlled, Double-Blind, Randomized, Phase 2 Study to Evaluate the Effect of Obicetrapib 10 mg Daily in Combination With Ezetimibe 10 mg Daily as an Adjunct to High-Intensity Statin Therapy: The ROSE 2 Study
Status: Completed, Estimated PCD: 2022-08-12
Clinical trial
A Double-blind, Randomized, Placebo and Ezetimibe Controlled, Multicenter Study to Evaluate Safety, Tolerability and Efficacy of AMG 145 on LDL-C in Combination With Statin Therapy in Subjects With Primary Hypercholesterolemia and Mixed Dyslipidemia
Status: Completed, Estimated PCD: 2013-11-12
Clinical trial
A Double-blind, Randomized, Placebo and Ezetimibe-controlled, Multicenter Study to Evaluate Safety and Efficacy of Lipid Lowering Monotherapy With AMG 145 in Subjects With a 10-Year Framingham Risk Score of 10% or Less
Status: Completed, Estimated PCD: 2013-10-10
Clinical trial
A Randomized, Double Blind, Parallel, Multi-center, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of DW1125 and DW1125A in Patient With Primary Hypercholesterolemia or Mixed Dyslipidemia
Status: Completed, Estimated PCD: 2023-04-13
Clinical trial
A Phase 2 Study to Evaluate the Safety and Efficacy of PCSK9 Inhibitor AK102 in Patients With Homozygous Familial Hypercholesterolemia (HoFH)
Status: Completed, Estimated PCD: 2021-03-15
Clinical trial
A Randomized, Placebo- and Ezetimibe-controlled, Dose-ranging Study to Evaluate Tolerability and Efficacy of AMG 145 on LDL-C in Hypercholesterolemic Subjects With a 10-year Framingham Risk Score of 10% or Less
Status: Completed, Estimated PCD: 2012-03-02
Clinical trial
A Randomized, Multicenter Study to Evaluate Tolerability and Efficacy of AMG 145 on LDL-C, Compared With Ezetimibe, in Hypercholesterolemic Subjects Unable to Tolerate an Effective Dose of a HMG-CoA Reductase Inhibitor
Status: Completed, Estimated PCD: 2012-05-08
Clinical trial
CHOlesterol Lowering and Residual Risk in Type 2 Diabetes
Status: Completed, Estimated PCD: 2023-09-25
Clinical trial
A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of MK-0616 Compared With Ezetimibe or Bempedoic Acid or Ezetimibe and Bempedoic Acid in Adults With Hypercholesterolemia
Status: Not yet recruiting, Estimated PCD: 2025-07-21
Clinical trial
Effect of Early Initiation of Evolocumab and Combination Lipid-lowering Agent on Lipid Profiles Changes in Patients With Acute Coronary Syndrome Undergoing percuTAneous coronaRy Intervention: a Prospective, Randomized Controlled Trial
Status: Recruiting, Estimated PCD: 2025-11-01
Clinical trial
A Phase 3, Double-Blind Efficacy and Safety Study of Ezetimibe (SCH 58235) 10 mg in Addition to Atorvastatin Compared to Placebo in Subjects With Primary Hypercholesterolemia (Protocol P00692)
Status: Completed, Estimated PCD: 2001-07-27
Clinical trial
Effects of Ezetimibe, Simvastatin, and Vytorin on Reducing L5 in Patients With Metabolic Syndrome
Status: Completed, Estimated PCD: 2008-02-01
Clinical trial
Long-Term, Safety and Tolerability Study of SCH 58235 or Placebo in Addition to Atorvastatin in Subjects With Primary Hypercholesterolemia
Status: Completed, Estimated PCD: 2002-08-08
Clinical trial
Examination of the Effect of Ezetimibe on Glucose Metabolism - Randomized, Double-blind, Placebo-controlled Study in Type 2 Diabetes Mellitus Patients With Hypercholesterolemia - Phase 4, Protocol No. 367 (Also Known as SCH 58235, P06541)
Status: Completed, Estimated PCD: 2014-01-16
Clinical trial
A Multicenter., Rand., Double-Blind, Titration Study to Evaluate & Compare the Efficacy & Safety of Ezetimibe Plus Atorvastatin Vs Atorvastatin in Hypercholesterolemic Pts. at Moderately High Risk for CHD Not Adequately Controlled on Atorvastatin 20 Mg
Status: Completed, Estimated PCD: 2008-01-01
Clinical trial
CHORD1 - CHOlesterol Lowering and Residual Risk in Diabetes, Type 1
Status: Recruiting, Estimated PCD: 2027-07-01
Clinical trial
A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Lipid-Altering Efficacy, Safety, and Tolerability of SCH 58235 When Added to Ongoing Therapy With an HMG-CoA Reductase Inhibitor (Statin) in Patients With Primary Hypercholesterolemia, Known Coronary Heart Disease, or Multiple Cardiovascular Risk Factors
Status: Completed, Estimated PCD: 2001-07-27
Clinical trial
A Placebo-Controlled, Double-Blind, Randomized Phase 2 Study to Evaluate the Effect of Obicetrapib in Combination With Ezetimibe in Participants With Mild Dyslipidemia
Status: Completed, Estimated PCD: 2021-05-07
Clinical trial
Open-label, Long-term Study of Coadministration of Ezetimibe and Atorvastatin in Patients With Primary Hypercholesterolemia Who Have Not Reached LDL-cholesterol Target With HMG-CoA Reductase Inhibitors
Status: Completed, Estimated PCD: 2009-06-01
Clinical trial
Open-label, Long-term Study of Coadministration of Ezetimibe and Simvastatin in Patients With Primary Hypercholesterolemia Who Have Not Reached LDL-cholesterol Target With HMG-CoA Reductase Inhibitors
Status: Completed, Estimated PCD: 2009-06-01
Clinical trial
Comparison of Effects of Simvastatin Versus Ezetimibe on Intracellular Lipid and Inflammation in Obese Subjects
Status: Terminated, Estimated PCD: 2021-08-01
Clinical trial
A Phase III Efficacy And Safety Study of Ezetimibe (SCH58235) 10 mg in Addition to Atorvastatin or Simvastatin in the Therapy of Homozygous Familial Hypercholesterolemia
Status: Completed, Estimated PCD: 2001-05-24
Clinical trial
A Phase III, Randomized, Active Comparator-controlled, Clinical Trial to Study the Efficacy and Safety of MK-0653H in Japanese Patients With Hypercholesterolemia.
Status: Completed, Estimated PCD: 2017-01-18
Clinical trial
A Phase III, Open-label, Clinical Trial to Assess the Long Term Safety and Tolerability of MK-0653H in Japanese Patients With Hypercholesterolemia Who Have Inadequate LDL-C Control on Ezetimibe or Rosuvastatin Monotherapy
Status: Completed, Estimated PCD: 2017-12-11
Clinical trial
A Phase III, Randomized, Active Comparator-controlled Clinical Trial to Study the Efficacy and Safety of MK-0653C in Japanese Patients With Hypercholesterolemia
Status: Completed, Estimated PCD: 2016-05-30
Clinical trial
Ezetimibe Phase IV Clinical Study in Patients With Hypercholesterolemia
Status: Completed, Estimated PCD: 2010-05-01
Clinical trial
A Placebo-Controlled, Double-Blind, Randomized, Phase 3 Study to Evaluate the Effect of Obicetrapib 10 mg and Ezetimibe 10 mg Fixed Dose Combination Daily on Top of Maximally Tolerated Lipid-Modifying Therapy in Participants With Heterozygous Familial Hypercholesterolemia (HeFH) and/or Atherosclerotic Cardiovascular Disease (ASCVD) or Multiple ASCVD Risk Factors
Status: Recruiting, Estimated PCD: 2024-10-01
Clinical trial
A Phase III Double-Blind Efficacy and Safety of Ezetimibe (SCH 58235) 10 MG in Addition to Atorvastatin in Subjects With Coronary Heart Disease or Multiple Cardiovascular Risk Factors and With Primary Hypercholesterolemia Not Controlled by a Starting Dose (10 mg) of Atorvastatin
Status: Completed, Estimated PCD: 2001-11-16
Document
DailyMed Label: Zetia
Organization
Rebel Distributors Corp.
Document
DailyMed Label: Ezetimibe
Organization
Proficient Rx LP
Organization
DIRECT RX
Document
DailyMed Label: EZETIMIBE
Organization
Camber Pharmaceuticals, Inc.
Organization
Zydus Lifesciences Limited
Organization
Organon LLC